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SUMMARY PAGE 
THE PROBLEM 
A computor library of the antimotion sickness drug literature has been established 
at the Naval Aerospace Medical Institute. A review of this literature i s  reported 
here. 
FIN DINGS 
The over-all effectiveness of the antihistamines was 70.6%; for the belladonnas it 
was 50.1%, and for the phenothiazines it was 44.5%. The over-all results of British 
studies indicated a greater effectiveness for the belladonnas than for the antihistamines, 
the reverse of U . S . studies. 
The effectiveness of the individual drugs against motion sickness i s  also reported. 
The over-all effectiveness of the drugs i s  compared in sea, air, and experimental 
motion studies. 
.. 
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INTRODUCTION 
Computor facilities available today are designed for the storage and retrieval of 
large amounts of data, and the literature on antimotion sickness drugs i s  well suited for 
computor procedures. The large proportion of th is  literature has been published in the 
last twenty years, and these studies have been similar in techniques used, methods of 
reporting,and in drug comparisons. The increased sea and especially air travel, both 
civilian and military, gives added importance to these drugs. The availability of an 
up-to-date computor library of reports on these drugs to permit rapid surveys of this 
literature should be of value. 
Such a computor library has been established at the Naval Aerospace Medical 
Institute, Pensacola, Florida, with information gained from a literature review in 
preparation for research on these drugs (91,92). The results of a similar review made 
by the Army-Navy-Air Force Motion Sickness Team preparatory to their Brmerhaven 
studies also were incorporated into this survey (5,83). The value of such a study i s  in 
the large number of subjects studied with the various drugs,the diverse stress conditions, 
and the variety of investigators presenting the reports (lo,%). The obvious disadvantage 
i s  that similar emphasis i s  given to reports with varying degrees of strictness in experi- 
mental design . What follows is  limited to a literature survey on the antimotion sick- 
ness drugs. 
PROCEDURE 
The available literature concerning the effectiveness of the antimotion sickness 
drugs was reviewed. The pertinent facts concerning each study were entered on a 
form for introduction into the computor. A copy of the form i s  reproduced on page 2. 
The items were coded for the computor program. After these data were entered 
into the computor, the groupings presented in the results section of this paper were 
obtained. Only a few special military reports were included as identical data for 
most reports were found in the published literature. This prevented duplication and 
also avoided quoting literature that i s  not generally available. 
The percentage effectiveness of the drugs reported here was obtained by use of 
the following formula (55) except in a few studies where insufficient data were given: 
% vomiting in placebo group - % vomiting in drug group X 100 
% vomiting in placebo group 
1 
t 
21, Dosage---------------------------------- 
22. Therapeutic/prophylactic use--------------- 
. 
23. Route of administration-------------------- 
24. Per cent vomiting with placebo------------- 
25. Side effects reported with placebo----------- 
L 
RESULTS AND DISCUSSION 
The computations are presented in Tables I-V. The maior portion of these drugs 
can be divided into several large divisions as indicated below. The over-all percentage 
effectiveness for each drug (Table 1) i s  shown in parenthesis following the drug name in 
each division . 
A N  TI  H IS TAM IN ES 
The antihistamines have been employed against motion sickness since their intro- 
duction by Gay and Carlinger in 1949 (41-43). Literature on the antihistamines swvey- 
ed in the present study involved over 14,000 subjects and 53 experiments.* 
effective and well-established drugs in this group were dimenhydrimate (72.9%) (1,73, 
74,80,81), cyclizine (71.2%) (60), meclizine (71.5%) (36,39,50,57,62), and diphen- 
hydramine (62.0%) (51). The side effect of drowsiness i s  reported to be a limiting 
factor with the use of dimenhydrimate and diphenhydramine (6). Cyclizine and 
meclizine are reported to produce less drowsiness. A low incidence of side effects 
i s  also reported for buclizine (75.0%) (33) and cinnarazine (60.0%) (83) which are 
promising new additions to this group. The combination of diphenhydramine with 
hyoscine (66.0%) and with hyoscine aminoxide (50.0%) would tend to indicate that, 
in general, the combinations are no more effective than the most active principal in 
them (21,45). Overall, this group of drugs was reported to be 70.6 per cent effective 
in preventing motion sickness. 
The most 
BELLADONNAS+ 
The belladonnas have had long and extensive use as motion sickness preventives 
and as a group in this survey were 50.1 per cent effective in 25 experiments involving 
3015 subjects. Hyoscine was 62.9 per cent (32,46), followed by benztropine (58.0%), 
atropine (50.0%), trihexyphenidyl (36.0%), and hyoscine aminoxide (24.0%) (31) 
among others. Hyoscine has long had the support of British investigators as being one 
of the most effective antimotion sickness preparations. The side effects of dry mouth, 
blurred vision, and drowsiness have been reported with i t s  use. With prolonged use 
disturbing dreams have also been reported (24,51). The synthetic belladonnas have 
fewer side effects (17,71) but also appear to be less effective,with the possible excep- 
tion of benztropine (one study) (5). Hyoscine in the 0.6 mg dose seems to be the drug 
of choice in thisgroup. 
- - - - - - - - - -  
*(refs. 3,4,7,8,11,16-19,20,22,23,25-29,37,38,51,53,56,59,66,70,82,~,94) 
+(refs. 14,15,34,48,49,52,55,56,61,63,64,67-69,75-78,89,90) 
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Table I 
' Effectiveness of Drugs in Preventing Motion Sickness Listed by Generic Names 
No. of Effectiveness No. of 
Drug Subjects Per Cent Studies 
B ena c t yz in e 
Ben z tropine 
Buclizine 
Caramiphen 
Cyc I izine 
C ycr i m i ne 
Chlorpromazine 
Chlorcyclizine 
Die thaz i ne 
Dimenhydrinate 
Dimenhydrinate + 
H yosc i ne 
Diphemanil 
Dimenhydrinate + 
E thopropazine 
Hyoscine Aminoxide 
H yosc in e 
Meclizine 
Meprobamate 
Nislamide 
Orphenadrine 
Promazi ne 
Pro met haz i ne 
Perphenazine 
Procycl idine 
Proch lorperaz ine 
Pyrathiazine 
Phenirarnine 
Phenyl tatoxamine 
Trifluoperazine 
Trimethobenzamine 
T r i  hexyphenidyl 
Diphen hydrarnine 
Promethazine + 
G I utet himide 
d -A rnp he ta m i ne 
T h i e  thy1 peraz ine 
Hyoscine Aminoxide 
d-Amphetamine 
61 
264 
587 
86 
21 28 
95 
139 
193 
803 
5184 
1234 
93 
117 
960 
302 
271 3 
2736 
440 
127 
94 
67 
3977 
73 
192 
518 
82 1 
1156 
1 1 1  
468 
43 
625 
2053 
80 
150 
168 
42 5 
3.50 
58 .oo 
75 .OO 
1.50 
71.24 
47.00 
21.80 
37.50 
2 .oo 
72.91 
66.02 
8 .OO 
50.00 
45.52 
24.41 
62.96 
67.98 
75.00 
19.70 
7.00 
5.00 
64.33 
25.00 
30.09 
39.81 
62.05 
59.82 
5 .OO 
69.00 
0.50 
36.44 
62.1 1 
50 .OO 
21.20 
64.00 
35.00 
1 
1 
2 
1 
6 
1 
1 
2 
1 
15 
9 
1 
1 
2 
3 
22 
12 
1 
1 
1 
1 
14 
1 
2 
4 
2 
3 
1 
2* 
1 
5 
9 
1 
2 
4 
2 
~~ 
"Tested for therapeutic effect and not for prophylactic effect. 
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I 
PHENOTHIAZINES' 
The phenothiazines have proven to be excellent antiemetics for chemically 
induced nausea; however, this does not appear to be directly related to potency in 
preventing motion sickness. Chlorpromazine which i s  reported to be only 21.8 per 
cent effective against motion sickness i s  an example of this. 
be the best established preparation in t h i s  group (9). It has an over-all effectiveness 
of 64.3 per cent in 14 studies (44). Prochlorpemzine (39.8%) (12,88) and triflvopera- 
zine (69.0%) (35,84), which was tested for therapeutic effect and not for prophylactic 
effect, appear to be promising dnrgs; however, at present too few reports on them are 
available. Part of the success of this group of drugs against motion sickness may be 
due to relief of some of the psychic factors which are of great importance in suscepti- 
bi l i ty to motion sickness. Side effects of drowsiness, decreased alertness, and hypo- 
tension have been reported with these preparations. This i s  a very active area of drug 
research, however, and i t  i s  possible that other effective drugs w i l l  be found here. 
A t  present, however, further investigation i s  indicated before the phenothiazines are 
well established as antimotion sickness drugs. Oher tranquilizer drugs such as the 
rauwolfias have not proven to be effective against motion sickness (30,86). 
Promethazine appears to 
MO NAM I N E  0x1 DASE IN H IB I TORS 
The monamine oxidase inhibitors have not proven to be significantly effective 
against motion sickness. 
bi l i ty with them (5,30). 
In fact, some studies have reported a heightened suscepti- 
V ITAM INS 
Vitamin preparations, although they have reported effectiveness against vertigo 
from atherosclerosis and against nausea of pregnancy, have been uniformly unsuccessful 
against motion sickness (5). 
MISCELLANEOUS 
There i s  one report that meprobamate was 75 per cent effective, but again further 
investigation seems indicated before i t s  use i s  established in this area (40). 
Trimethobenzamide has been used against motion sickness; however, in the only 
study available to this survey it was ineffective as a prophylactic measure (89). 
The use of d-amphetamine against motion sickness has been reported in four studies 
in which it was 64.0 per cent effective (2,13,54,58). When combined with other drugs 
i t s  effectiveness i s  not diminished (16),and therefore it may be of value in counteracting 
the drowsiness reported with several of the preparations. 
* (ref s. 47,65,72,87) 
- - _ _ - - - - - _  
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COMMENTS 
In Table II it i s  noted that drug effectiveness diminished with exposure to motion 
of more than twenty-four hours. This would be expected as susceptibility i s  increased 
with time in exposure. 
Table II 
Length of Exposure as Related to Effectiveness Against Motion Sickness 
No. of Effectiveness No. of 
Subjects Per cent Studies 
Less than 24 hrs. 13162 67.32 69 
24 hrs. or more 16273 55 . 35 68 
The type of motion i s  also an important consideration. The drugs were more 
effective in flying studies than in studies at sea. It i s  noted that, with experimentally 
produced motion, which eliminates the milder test situations, the antimotion sickness 
drugs were generally less effective (Table 111)  A more careful selection for suscepti- 
bi l i ty of subjects in the experimental conditions may have also been a factor. 
Table 1 1 1  
Effectiveness of al l  Types of Antimotion Sickness Drugs as Related to Type of Exposure 
No. of Effectiveness No. of 
Subjects Per cent Studies 
Sea 16502 55.77 74 
Air 8467 72.74 29 
Exp. Sea 353 33.84 5 
Swing 141 39.33 2 
Exp. Air 3776 59 . 54 24 
6 
. 
In Table N the antihistamines are listed as 70 per cent effective while hyoscine 
was 50 per cent effective. Table V, however, indicates reverse results when the 
British and U. S. studies are considered separately. These were in the main a l l  
military studies using placebos and double-blind conditions; therefore, it i s  difficult 
to explain these differences. A variation in the strength of stimulus in the various 
studies may be part of the anmer. It may be that the antihistamines have adequate 
effects against only the milder stresses due to motion, while hyoscine i s  effective not 
only in mi ld but also in the more severe stresses. In carefully controlled studies on 
effectiveness of antimotion sickness drugs at the Naval Aerospace Medical Institute 
utilizing the Slow Rotation Room the results were in general agreement with the British 
reports (89). 
Table IV 
Type of Drugs as Reported for Over411 Effectiveness 
No. of E f f  ectiveneo No. of 
Type Subjects Per cent Studies 
Antihistamines 14-402 70.58 53 
Antihistamine + 
Bel ladonna 1301 65 -27 9 
Belladonna 3015 50.10 25 
Synthetic 
Belladonnas 2678 23.19 14 
Moncamine Oxidose 
Inhibitors 127 19.70 1 
Phenothiazines 1363 44.91 7 
Tranqu i I izers 822 63.33 4 
V i  tamins 336 5 000 3 
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Table V 
Comparison of British and U. S. Reports of Effectiveness 
No. of Effectiveness No. of 
S u bi ects Per cent Studies 
Anti histamines 
British 807 39 11 
u. s. 2496 70 36 
H yosc in e 
British 417 83 6 
u. s. 997 52 19 
In some of the studies reported in  this survey, the proper research conditions of 
placebos and double blind (85) were not used. The computor cannot improve upon 
poorly collected data; therefore, a test design incorporating these features i s  strongly 
recommended for any future studies. The computor library i s  continuing to be expanded 
by additional studies from the literature and by new reports as they are published. 
Motion sickness is  a complex and unique response. There appears to be no corre- 
lation between potency as an antimotion sickness preparation and effectiveness of the 
same drugs as antihistamines against Parkinsonism, with other types of nausea and 
vertigo, and even as antiemetics against chemically induced nausea. It i s  therefore 
important that these drugs be tested against conditions which evoke motion sickness 
before any recommendations are made for their use against motion sickness. 
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